NCT04883138View on ClinicalTrials.gov

Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients

PHASE1TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

January 11, 2022

Study Completion Date

January 11, 2022

Conditions

COVID-19

Interventions

DRUG

GIGA-2050

Recombinant Hyperimmune Polyclonal Antibody

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Lead Sponsor

All Listed Sponsors

lead

GigaGen, Inc.

INDUSTRY